Cramer-Morales K, et al. (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122, 1293-304 23836560

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y104-p - RAD52 (human) ▲

Modsite: DLNNGKFyVGVCAFV SwissProt Entrez-Gene Orthologous residues RAD52 (human): Y104‑p, RAD52 (mouse): Y105‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  bone marrow [RAD52 (mouse), homozygous knockout] Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE BCR-ABL1 (human) co-immunoprecipitation Downstream Regulation Effect of modification (process):  DNA repair, induced Comments:  single-strand annealing but not homologous recombination repair